LyondellBasell Industries N.V. LYB
LyondellBasell Industries N.V. is an industrial organic chemicals issuer listed as LYB on NYSE. This free Atlas page links SEC CIK 1489393, Nasdaq Trader and TradingView NYSE:LYB, related symbols and the workstation route before a full report is run.
LYB public profile
Industrial organic chemicals issuer. Atlas tracks LYB through its NYSE listing record, chart route and source links.
LYB trades on NYSE. SEC CIK 1489393. Chart route NYSE:LYB.
Nasdaq Trader is the listing identity source for LyondellBasell Industries N.V.. Atlas files LYB under USA Stocks for browsing. The canonical public URL is /stocks/LYB/. The workstation link below opens the fuller research run.
Market Wit preview
LyondellBasell's first-quarter earnings report reads like a chemistry lab's attempt at stand-up comedy: revenues up 7% thanks to higher average sales prices, but then sales volumes tumble 6% because, well, nobody was buying. It's like mixing equal parts optimism and kitchen-sink excuses, then watching the reaction fizzle out. The company's $3.63 billion in net inventory feels less like a stockpile and more like a warehouse of unsold promises (source: LYB SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1489393/000148939326000028/lyb-20260331.htm).
Run the full workstation report for the complete source rail, saved history, export controls, and the full Market Wit file for LYB.
What changed for LyondellBasell Industries N.V. today
LyondellBasell Industries N.V. (LYB) reported a 7% increase in revenues for the first quarter of 2026, driven by higher average sales prices for many of its products. However, the company also faced a 6% decrease in revenues due to lower sales volumes, driven by lower demand and unplanned downtime. The contrasting trends highlight the challenges the company faces in balancing pricing power with market demand (source: LYB SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1489393/000148939326000028/lyb-20260331.htm).
LyondellBasell is a global leader in the production of chemicals, plastics, and refining products. The company’s broad range of products and technologies serves various industries, including healthcare and pharmaceuticals, where its solutions aim to enhance efficiency and provide best-in-class care. The company’s ability to innovate and adapt to market demands is crucial for its continued success (source: LyondellBasell, https://www.lyondellbasell.com).
In its latest 10-Q filing, LyondellBasell reported operating income of $239 million and net cash used in operating activities of $269 million for the period ending March 31, 2026. The company’s assets total $33.96 billion, with stockholders' equity attributable to the parent amounting to $10.04 billion. Cash and cash equivalents stand at $2.63 billion, while inventory nets $3.63 billion. These figures provide a snapshot of the company’s financial health and operational efficiency (source: LYB SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/1489393/000148939326000028/lyb-20260331.htm).
For a deeper dive into LyondellBasell’s financial performance, the TradingView chart provides a visual representation of the company’s stock performance over time. This chart, along with the company’s financial filings, offers a comprehensive view of its market positioning and investor sentiment (source: TradingView, https://www.tradingview.com/symbols/NYSE-LYB/).
While LyondellBasell has made strides in increasing revenues through higher sales prices, the decrease in sales volumes remains a significant concern. The company’s ability to manage inventory levels and capital expenditures will be critical in navigating the current market environment. Future earnings reports and regulatory filings will provide further insights into the company’s strategic direction and operational performance.
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
Atlas has no approved static OHLC cache attached for LYB yet, so the profile renders the verified TradingView chart route directly and keeps the full-chart link as fallback.
Run an Atlas research workflow on LYB
FreedomCore Atlas operates research workstation templates for company snapshots, DCF, LBO, KYC, NAV tie-outs, and council-grade equity briefs. Each workflow uses public-source filings and structured prompts.
Open Atlas workstation ->Save LYB research and exports
Free Atlas users can run full browser research reports from the workstation. Atlas Pro adds 25 custom runs a day, saved research history, email delivery, PDF/CSV exports, and a 25-symbol watchlist. £12/mo founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
LYB FAQ
What is LyondellBasell Industries N.V. (LYB)?LyondellBasell Industries N.V. is an industrial organic chemicals issuer listed as LYB on NYSE. This free Atlas page links SEC CIK 1489393, Nasdaq Trader and...
LyondellBasell Industries N.V. is an industrial organic chemicals issuer listed as LYB on NYSE. This free Atlas page links SEC CIK 1489393, Nasdaq Trader and TradingView NYSE:LYB, related symbols and the workstation route before a full report is run.
What does Atlas show for LYB?The LYB page gives the free Atlas profile for LyondellBasell Industries N.V.: listing identity, chart route, related symbols, source authority and the workstation...
The LYB page gives the free Atlas profile for LyondellBasell Industries N.V.: listing identity, chart route, related symbols, source authority and the workstation route. The chart route is NYSE:LYB; the stable page route is /stocks/LYB/. Visible source links include SEC EDGAR CIK 1489393, Nasdaq Trader and TradingView NYSE:LYB. Atlas files LYB under USA Stocks for browsing.
How often is the LYB page updated?The /stocks/LYB/ URL is stable. Atlas updates the free LYB page when the symbol-universe record, listing identity, source links, chart route, related-symbol links or...
The /stocks/LYB/ URL is stable. Atlas updates the free LYB page when the symbol-universe record, listing identity, source links, chart route, related-symbol links or published public answer changes.
Which sources does Atlas use for LYB?For LYB, Atlas starts with SEC EDGAR CIK 1489393, Nasdaq Trader and TradingView NYSE:LYB. The SEC CIK 1489393 route is the issuer filing anchor. Nasdaq Trader confirms...
For LYB, Atlas starts with SEC EDGAR CIK 1489393, Nasdaq Trader and TradingView NYSE:LYB. The SEC CIK 1489393 route is the issuer filing anchor. Nasdaq Trader confirms the listed-symbol identity used by the public directory. NYSE:LYB is the chart route shown on the free page. Full workstation reports may add fresh filings, issuer documents, holdings, news, macro context or model-reviewed notes when available.
Can Atlas run a full research brief on LYB?Yes. The workstation can open LYB, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open LYB, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this LYB page investment advice?No. The LYB page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a buy or sell instruction, or a...
No. The LYB page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a buy or sell instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-06-20. Browse FreedomCore Atlas research notes →